Transplant Care and Immunosuppression Practices at Pediatric Kidney Transplant Centers and Their Association With Re‐transplantation After Graft Failure
Pediatric Transplantation · 2026-11 · 30 (11)
DOI: 10.1111/petr.70516 ↗Abstract
ABSTRACT Background There is a paucity of data on how to manage children with failed kidney transplants in order to optimize their access to future transplants. Our objective was to understand how system‐level differences in transplant care and immunosuppression management after graft failure are associated with access to a second kidney transplant in children. Methods To achieve our objective, we surveyed US pediatric kidney transplant centers about their practices. We then examined the relation between each center's approach in delivering follow‐up care, transitioning care, and immunosuppression management after graft failure with access of children to re‐transplantation between 2005 and 2019 according to the US Renal Data System using Fine‐Gray models. Results 43/84 surveyed programs who served 1388 pediatric patients with graft failure responded. Although programs had variable practices in terms of frequency of follow‐up visits and age of transition from pediatric to adult care, these practices were not associated with access to re‐transplantation. Regarding immunosuppression management, pediatric kidney transplant recipients at centers whose respondents did not oversee the weaning of immunosuppression after graft failure had a 37% reduced likelihood of re‐transplantation (95% CI: 17%–53%). Centers that continued immunosuppression in children receiving dialysis after graft failure until there was no residual graft function had a 39% reduced likelihood of re‐transplantation (95% CI: 17%–55%) compared to centers that withdrew immunosuppression after a pre‐defined period. Conclusions Management of pediatric transplant recipients with graft failure is variable at US pediatric kidney transplant centers, and variability in immunosuppression management practices was associated with the likelihood of re‐transplantation.
EUVIMED